SEEL – seelos therapeutics, inc. (US:NASDAQ)
Stock Stats
News
10/24
04:05 pm
seel
Medium
Seelos Announces Second Postponement of its Annual Meeting of Stockholders
10/15
09:27 am
seel
Medium
Seelos gets Nasdaq delisting notice Oct. 15, 2024 9:25 AM ET By: Preeti Singh , SA News Editor [Seeking Alpha]
10/15
09:00 am
seel
High
Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market
9/25
08:00 am
seel
Low
Seelos Therapeutics Announces 1-for-16 Reverse Stock Split
9/24
08:00 am
seel
Medium
Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD
11/14
07:33 pm
seel
High
Form SC 13G/A SEELOS THERAPEUTICS, Filed by: Lind Global Fund II LP
11/5
01:46 pm
seel
Low
Form SC 13G SEELOS THERAPEUTICS, Filed by: AdvisorShares Trust
10/24
04:16 pm
seel
Medium
Form DEFA14A SEELOS THERAPEUTICS,
10/24
04:11 pm
seel
Medium
Form 8-K SEELOS THERAPEUTICS, For: Oct 24
10/15
09:16 am
seel
Medium
Form 8-K SEELOS THERAPEUTICS, For: Oct 14
Show more
Top News Gainers
11/18 Seelos Therapeutics Receives FDA Fast Track Designation for Intranasal Racemic Ketamine (SLS-002) 42.7%
2/14 Form 4 SEELOS THERAPEUTICS, For: Feb 13 Filed by: Mehra Raj 21.3%
4/13 Form DEF 14A SEELOS THERAPEUTICS, For: May 15 14.5%
2/13 Seelos Therapeutics Announces Closing of Public Offering of Common Stock 10.8%
1/7 Form 4 SEELOS THERAPEUTICS, For: Jan 06 Filed by: Smith Robin L 10.6%
11/14 Seelos Therapeutics Inc (NASDAQ: SEEL) is now covered by analysts at Benchmark Co.. They set a "speculative buy" rating and a $4.00 price target on the stock. 9.3%
4/30 Seelos Therapeutics Receives Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome 9.2%
4/24 Form 8-K SEELOS THERAPEUTICS, For: Apr 21 9.1%
3/17 Form 10-K SEELOS THERAPEUTICS, For: Dec 31 8.4%
1/16 Form SC 13G SEELOS THERAPEUTICS, Filed by: Phoenixus AG 7.0%
Top News Decliners
6/27 Form 8-K SEELOS THERAPEUTICS, For: Jun 27 -19.4%
3/11 Seelos Therapeutics Announces European Medicines Agency Guidance to Design an Open-Label Pivotal Study for SLS-005 in Sanfilippo Syndrome -17.9%
8/23 Form 424B3 SEELOS THERAPEUTICS, -16.7%
3/11 Seelos Therapeutics Announces Proposed Public Offering of Common Stock -15.7%
2/7 Form S-1/A SEELOS THERAPEUTICS, -11.0%
4/1 Form PRE 14A SEELOS THERAPEUTICS, For: May 15 -10.7%
11/20 Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002) -10.5%
5/1 Psychedelic Products Gain Traction for Medicinal Purposes -9.8%
8/1 Seelos Therapeutics Reports Q2 2019 Pipeline Update -9.7%
1/22 Seelos Therapeutics Announces Updates to SLS-005 (trehalose) Programs for Europe and U.S. -9.1%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3